Eloxx Pharmaceuticals, Inc. — Q2 2020 Form 10-Q
Reporting period: Three and six months ended June 30, 2020. The company is a clinical-stage biopharmaceutical developer with no product revenue; its lead candidate, ELX-02, is in Phase 2 development for cystic fibrosis (CF). Financial amounts below are in millions of dollars unless stated otherwise.
Key financial results
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $3.5 | $7.3 | $8.1 | $13.4 |
| General and administrative expense | $4.1 | $7.0 | $9.3 | $12.9 |
| Restructuring charges | — | — | $4.0 | — |
| Net loss | $(7.9) | $(14.4) | $(21.8) | $(26.4) |
| Net loss per share | $(0.20) | $(0.40) | $(0.54) | $(0.73) |
| Cash used in operating activities | — | — | $(18.2) | $(18.8) |
There is no revenue or gross margin to report. The smaller Q2 and six-month losses primarily reflect lower R&D spending, including reduced subcontractor, consultant and adviser costs amid enrollment delays, and lower G&A costs. Lower spending does not by itself indicate improved clinical progress.
Balance sheet and liquidity
- At June 30, 2020, cash and cash equivalents were $30.3 and marketable securities were $6.8, for $37.1 combined, compared with $56.3 at December 31, 2019. Cash, cash equivalents and restricted cash totaled $30.4.
- Current assets were $39.0 and current liabilities $10.8; working capital was approximately $28.2. Stockholders’ equity was $20.3, down from $36.2 at year-end 2019.
- Debt carrying value was $13.0, comprising $5.1 current and $8.7 long-term. The term loan bears a 5.75% stated rate at June 30, with principal payments underway and maturity in January 2023; its effective rate was 10.85%. The company also received a $0.8 PPP loan at 1% interest, potentially subject to forgiveness under program terms.
- Management said available cash, cash equivalents and marketable securities were expected to fund anticipated needs through at least 12 months from issuance of the financial statements and to support operations through anticipated CF Phase 2 top-line data. The company has no product revenue, expects continuing losses, and may need additional financing.
Material developments and outlook
- COVID-19 temporarily paused enrollment in the Phase 2 CF trials. By June 17, enrollment had resumed in Israel and Europe; the U.S. trial remained paused. The company aimed to complete enrollment and report top-line data as soon as feasible, but provided no firm timing. COVID-19 could disrupt trial access, CRO and site operations, and regulatory review.
- The company discontinued the second cohort planned under its Phase 2 nephropathic cystinosis study after study-design limitations made WBC cystine reductions difficult to assess. First-cohort results met the primary safety endpoint and showed biological activity at doses above 0.5 mg/kg/day; the company said it would review the data to assess a possible revised study.
- On February 24, the board approved an organizational realignment that eliminated 13 positions. The first-half charge was $4.0, including $2.1 of accelerated stock-based compensation. Management projected approximately $4.9 in annual cost savings and approximately $2.4 in fiscal 2020 savings net of severance costs.
- The company reported preclinical work in ADPKD and inherited retinal disorders, but these programs remained preclinical. FDA CF orphan-drug designation was announced on August 4, 2020, after quarter-end; designation is not marketing approval.
- Management expects continued losses and cash use. Potential expense increases include advancing clinical and preclinical programs; inability to secure financing could force reductions or deferrals. Key risks include clinical safety and efficacy uncertainty, enrollment delays, COVID-19 disruption, reliance on third parties, and the need for additional capital.
- No material pending litigation was reported. Management stated disclosure controls were effective as of June 30, 2020, with no material changes in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether CF Phase 2 enrollment resumed in the U.S., trial enrollment completed, and top-line data timing or results were subsequently disclosed.
- Whether the cystinosis findings lead to a redesigned study, and the evidence supporting the reported biological activity.
- Cash burn, financing needs and runway relative to the company’s stated 12-month liquidity outlook; also verify any later equity or debt issuance.
- Debt repayment obligations and PPP loan forgiveness status, if applicable.
- Whether projected restructuring savings were achieved and whether cost reductions affect development execution.